Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CASP1 | P29466 | 3/20 | 0.45 |
| ▸ | CASP7 | P55210 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772997 | 0.88 | MAPK14 (0.55) | MAPK14BRD4 | |
| SCHEMBL6624696 | 0.88 | MAPK14 (0.57) | MAPK14BRD4 | |
| SCHEMBL6779673 | 0.86 | MAPK14 (0.62) | MAPK14CYP1A2CYP2C9CYP2C19BRD4 | |
| SCHEMBL6771592 | 0.85 | MAPK14 (0.56) | MAPK14BRD4 | |
| SCHEMBL6774285 | 0.85 | MAPK14 (0.58) | MAPK14CYP1A2CYP2C9CYP2C19BRD4 | |
| SCHEMBL6772274 | 0.84 | MAPK14 (0.60) | MAPK14BRD4 | |
| SCHEMBL6768473 | 0.84 | MAPK14 (0.55) | MAPK14CYP1A2CYP2C9CYP2C19BRD4 | |
| SCHEMBL6608979 | 0.84 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL6775306 | 0.83 | MAPK14 (0.59) | MAPK14CYP1A2CYP2C9CYP2C19BRD4 | |
| SCHEMBL6773269 | 0.83 | MAPK14 (0.54) | MAPK14BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-01-16 | — | — | US | claimed |
| US-6727364-B2 | ANTIINFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | IL4, IL1A, IL2 | MAPK14 3429/4885ALDH1A1 289/4885CYP1A2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.